Brief report · 26 Nov 2025
Review articlePublished 27 Feb 2020
Will Probiotics Provide the Answer for Therapy of Non-alcoholic Fatty Liver Disease (NAFLD)? - A Systematic Review
1Centre for Human Reproduction 721, G.T.B. Nagar, Jalandhar, Punjab, India; 2Ex-Rotunda - A Centre for Human Reproduction 672, Kalpak Garden, Bandra (W) Mumbai, India; 3Swami Satyanand Hospital, Near Nawi Kachehri, Baradri, Jalandhar, Punjab, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
As per current definition recognized by Food and Agricultural Organization of the United Nations (FAO) and world health organization (WHO) working group experts is that probiotics are live strains of strictly selected microorganisms, which once administered in adequate amounts, give a health benefit to the host. Globally non-alcoholic fatty liver disease (NAFLD) represents the liver problems of metabolic syndrome (Met S) that is also mostly related to obesity type2 diabetes mellitus (T2DM), as well as dyslipidemia. The correlation between gut microbiota and NAFLD has been emphasized recently. Lot of evidence is there that gut microbiota influences hepatic lipid metabolism as well as affects the correlation between pro and anti-inflammatory effectors within the liver. Though experimental studies have shown a correlation between gut microbiota dysbiosis and NAFLD exactly getting the answers of mode by which gut dysbiosis causes NAFLD is a problem. The probable pathophysiology which intertwines gut microbiota dysbiosis to NAFLD might be summed up as interrupting the energy balance among harvest as well as energy expenditure (EE), aiding in hepatic inflammation (interfering with intestinal integrity, stimulate endotoxaemia and start inflammatory cascades associated with cytokines liberation) and changes in biochemistry, metabolism and gut microbiota associated metabolites (like bile acids, short chain fatty acids (SCFA’s), Aromatic amino acid (AAA) derivatives, branched chain amino acid (BCAA), choline, ethanol). With the deposit that probiotics or synbiotics might reverse the gut microbiota associated dysbiosis in cases of NAFLD, work has escalated to evaluate the therapeutic efficacy of probiotics or synbiotics in NAFLD patients. Randomised controlled trials (RCT’S) done in recent times point that probiotics or synbiotics might better the tranmsaminases, steatohepatitis and decrease inflammation. Inspite of promising outcomes more further studies are warranted to get an insight in the full part that gut microbiota play in the formation of NAFLD and its future continuation. Moreover more results are required to know the effectiveness, safety profile and maintenance in the form of an innovative pharmacologic method for curing NAFLD.
Subjects
Biochemistry & BiotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Biochemistry & Physiology: Open Access.
Commentary · 26 Nov 2025
ROS: Diverse Roles, Disease, and Therapy
Short communication · 26 Nov 2025
Advancements in Liver Fibrosis: Diagnostics to Personalized Care
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalBiochemistry & Physiology: Open Access
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Kulvinder Kochar Kaur”
- BylineArticles whose byline prints “Gautam Allahbadia”
- BylineArticles whose byline prints “Mandeep Singh”